Filtered By:
Infectious Disease: Influenza
This page shows you your search results in order of date. This is page number 20.
Order by Relevance | Date
Total 16629 results found since Jan 2013.
Increasing Influenza vaccination uptake rates in the 65-year-old population
Ir Med J. 2023 Aug 17;116(7):805.NO ABSTRACTPMID:37606210
Source: Ir Med J - August 22, 2023 Category: General Medicine Source Type: research
Predictors of immune persistence induced by two-dose BBIBP-CorV vaccine in high-risk occupational population
CONCLUSIONS: From 28 days to 10 months after receipt of the second dose of the BBIBP-CorV vaccine, neutralizing antibody levels were substantially decreased, especially among men, among persons 50 years of age or older, among persons with the 0-14 d group, and among persons without history of influenza vaccination.TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR2100041705, ChiCTR2100041706.PMID:37604725 | DOI:10.1016/j.vaccine.2023.08.042
Source: Vaccine - August 21, 2023 Category: Allergy & Immunology Authors: Tian Yao Yana Guo Xiuyang Xu Xiaohong Zhang Shengcai Mu Junfeng Huo Zhiyun Wei Ling Liu Xiaoqing Li Hong Li Rongqin Xing Yongliang Feng Jing Chen Lizhong Feng Suping Wang Source Type: research
Influenza vaccine effectiveness against influenza A during the delayed 2022/23 epidemic in Shihezi, China
Vaccine. 2023 Aug 19:S0264-410X(23)00971-4. doi: 10.1016/j.vaccine.2023.08.039. Online ahead of print.ABSTRACTAfter the temporary end of COVID-19 in China in February 2023, the influenza epidemic peaked in March across many Chinese places. We recruited a total of 258 all-age subjects presenting influenza-like illness (ILI) in Shihezi city, China from January 1 to March 16, 2023, and tested for influenza virus infection. Using a test-negative design, we assessed influenza vaccine effectiveness (VE) of 56.3% (95% CrI: 13.6, 73.6) against medically attended, influenza illness during the delayed 2022/23 influenza epidemic. The...
Source: Vaccine - August 21, 2023 Category: Allergy & Immunology Authors: Yinxia Su Zihao Guo Xiu Gu Shengzhi Sun Kai Wang Songsong Xie Shi Zhao Source Type: research
Predictors of immune persistence induced by two-dose BBIBP-CorV vaccine in high-risk occupational population
CONCLUSIONS: From 28 days to 10 months after receipt of the second dose of the BBIBP-CorV vaccine, neutralizing antibody levels were substantially decreased, especially among men, among persons 50 years of age or older, among persons with the 0-14 d group, and among persons without history of influenza vaccination.TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR2100041705, ChiCTR2100041706.PMID:37604725 | DOI:10.1016/j.vaccine.2023.08.042
Source: Vaccine - August 21, 2023 Category: Allergy & Immunology Authors: Tian Yao Yana Guo Xiuyang Xu Xiaohong Zhang Shengcai Mu Junfeng Huo Zhiyun Wei Ling Liu Xiaoqing Li Hong Li Rongqin Xing Yongliang Feng Jing Chen Lizhong Feng Suping Wang Source Type: research
Influenza vaccine effectiveness against influenza A during the delayed 2022/23 epidemic in Shihezi, China
Vaccine. 2023 Aug 19:S0264-410X(23)00971-4. doi: 10.1016/j.vaccine.2023.08.039. Online ahead of print.ABSTRACTAfter the temporary end of COVID-19 in China in February 2023, the influenza epidemic peaked in March across many Chinese places. We recruited a total of 258 all-age subjects presenting influenza-like illness (ILI) in Shihezi city, China from January 1 to March 16, 2023, and tested for influenza virus infection. Using a test-negative design, we assessed influenza vaccine effectiveness (VE) of 56.3% (95% CrI: 13.6, 73.6) against medically attended, influenza illness during the delayed 2022/23 influenza epidemic. The...
Source: Vaccine - August 21, 2023 Category: Allergy & Immunology Authors: Yinxia Su Zihao Guo Xiu Gu Shengzhi Sun Kai Wang Songsong Xie Shi Zhao Source Type: research
Predictors of immune persistence induced by two-dose BBIBP-CorV vaccine in high-risk occupational population
CONCLUSIONS: From 28 days to 10 months after receipt of the second dose of the BBIBP-CorV vaccine, neutralizing antibody levels were substantially decreased, especially among men, among persons 50 years of age or older, among persons with the 0-14 d group, and among persons without history of influenza vaccination.TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR2100041705, ChiCTR2100041706.PMID:37604725 | DOI:10.1016/j.vaccine.2023.08.042
Source: Vaccine - August 21, 2023 Category: Allergy & Immunology Authors: Tian Yao Yana Guo Xiuyang Xu Xiaohong Zhang Shengcai Mu Junfeng Huo Zhiyun Wei Ling Liu Xiaoqing Li Hong Li Rongqin Xing Yongliang Feng Jing Chen Lizhong Feng Suping Wang Source Type: research
Influenza vaccine effectiveness against influenza A during the delayed 2022/23 epidemic in Shihezi, China
Vaccine. 2023 Aug 19:S0264-410X(23)00971-4. doi: 10.1016/j.vaccine.2023.08.039. Online ahead of print.ABSTRACTAfter the temporary end of COVID-19 in China in February 2023, the influenza epidemic peaked in March across many Chinese places. We recruited a total of 258 all-age subjects presenting influenza-like illness (ILI) in Shihezi city, China from January 1 to March 16, 2023, and tested for influenza virus infection. Using a test-negative design, we assessed influenza vaccine effectiveness (VE) of 56.3% (95% CrI: 13.6, 73.6) against medically attended, influenza illness during the delayed 2022/23 influenza epidemic. The...
Source: Vaccine - August 21, 2023 Category: Allergy & Immunology Authors: Yinxia Su Zihao Guo Xiu Gu Shengzhi Sun Kai Wang Songsong Xie Shi Zhao Source Type: research
Estimating SARS-CoV-2 infections and associated changes in COVID-19 severity and fatality
CONCLUSIONS: Since 2021, changes in the dominant SARS-CoV-2 variant, vaccination rollout, and the shift of infection to younger ages have reduced SARS-CoV-2 infection ascertainment. The same factors, combined with the improvement of patient management and care, contributed to a massive reduction in the severity and fatality of COVID-19.PMID:37599801 | PMC:PMC10432583 | DOI:10.1111/irv.13181
Source: Respiratory Care - August 21, 2023 Category: Respiratory Medicine Authors: Valentina Marziano Giorgio Guzzetta Francesco Menegale Chiara Sacco Daniele Petrone Alberto Mateo Urdiales Martina Del Manso Antonino Bella Massimo Fabiani Maria Fenicia Vescio Flavia Riccardo Piero Poletti Mattia Manica Agnese Zardini Valeria d'Andrea Fi Source Type: research
Effect of the SARS-CoV-2 Delta-associated G15U mutation on the s2m element dimerization and its interactions with miR-1307-3p
RNA. 2023 Aug 21:rna.079627.123. doi: 10.1261/rna.079627.123. Online ahead of print.ABSTRACTThe stem loop 2 motif (s2m), a highly conserved 41-nucleotide hairpin structure in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome, serves as an attractive therapeutic target that may have important roles in the virus life cycle or interactions with the host. However, the conserved s2m in Delta SARS-CoV-2, a previously dominant variant characterized by high infectivity and disease severity, has received relatively less attention than that of the original SARS-CoV-2 virus. The focus of this work is to identify...
Source: RNA - August 21, 2023 Category: Genetics & Stem Cells Authors: Caylee L Cunningham Caleb J Frye Joseph A Makowski Adam H Kensinger Morgan Shine Ella J Milback Patrick E Lackey Jeffrey D Evanseck Mihaela Rita Mihailescu Source Type: research
Estimating SARS-CoV-2 infections and associated changes in COVID-19 severity and fatality
CONCLUSIONS: Since 2021, changes in the dominant SARS-CoV-2 variant, vaccination rollout, and the shift of infection to younger ages have reduced SARS-CoV-2 infection ascertainment. The same factors, combined with the improvement of patient management and care, contributed to a massive reduction in the severity and fatality of COVID-19.PMID:37599801 | PMC:PMC10432583 | DOI:10.1111/irv.13181
Source: Respiratory Care - August 21, 2023 Category: Respiratory Medicine Authors: Valentina Marziano Giorgio Guzzetta Francesco Menegale Chiara Sacco Daniele Petrone Alberto Mateo Urdiales Martina Del Manso Antonino Bella Massimo Fabiani Maria Fenicia Vescio Flavia Riccardo Piero Poletti Mattia Manica Agnese Zardini Valeria d'Andrea Fi Source Type: research
Simultaneous administration of mRNA COVID-19 bivalent booster and influenza vaccines
We describe simultaneous influenza and mRNA COVID-19 bivalent booster vaccine administration between August 31-December 31, 2022, among persons aged ≥6 months in the Vaccine Safety Datalink (VSD) by COVID-19 bivalent booster vaccine type, influenza vaccine type, age group, sex, and race and ethnicity. Of 2,301,876 persons who received a COVID-19 bivalent booster vaccine, 737,992 (32.1%) received simultaneous influenza vaccine, majority were female (53.1%), aged ≥18 years (91.4%), and non-Hispanic White (55.7%). These findings can inform future VSD studies on simultaneous influenza and COVID-19 bivalent booster vaccine ...
Source: Vaccine - August 20, 2023 Category: Allergy & Immunology Authors: Tat'Yana A Kenigsberg Kristin Goddard Kayla E Hanson Ned Lewis Nicola Klein Stephanie A Irving Allison L Naleway Bradley Crane Tia L Kauffman Stanley Xu Matthew F Daley Laura P Hurley Robyn Kaiser Lisa A Jackson Amelia Jazwa Eric S Weintraub Source Type: research
Cysteamine-mediated blockade of the glycine cleavage system modulates epithelial cell inflammatory and innate immune responses to viral infection
Biochem Biophys Res Commun. 2023 Aug 15;677:168-181. doi: 10.1016/j.bbrc.2023.08.021. Online ahead of print.ABSTRACTTransient blockade of glycine decarboxylase (GLDC) can restrict de novo pyrimidine synthesis, which is a well-described strategy for enhancing the host interferon response to viral infection and a target pathway for some licenced anti-inflammatory therapies. The aminothiol, cysteamine, is produced endogenously during the metabolism of coenzyme A, and is currently being investigated in a clinical trial as an intervention in community acquired pneumonia resulting from viral (influenza and SARS-CoV-2) and bacter...
Source: Biochemical and Biophysical Research communications - August 19, 2023 Category: Biochemistry Authors: Douglas Fraser-Pitt Derry K Mercer Marie-Louise Francis David Toledo-Aparicio Daniel W Smith Deborah A O'Neil Source Type: research
Highly pathogenic avian influenza affects vultures' movements and breeding output
Curr Biol. 2023 Aug 14:S0960-9822(23)01000-X. doi: 10.1016/j.cub.2023.07.061. Online ahead of print.ABSTRACTAn exceptional highly pathogenic avian influenza (HPAI) outbreak due to H5N1 virus genotypes belonging to clade 2.3.4.4.b has been affecting birds worldwide since autumn 2021.1,2,3 Mortality caused by viral infection has been well documented in poultry and more recently in wild birds, especially in seabird-breeding colonies.4,5,6 However, there is a critical lack of knowledge about how terrestrial birds deal with HPAI virus infections in terms of behavior and space use, especially during the breeding season.7,8,9 Und...
Source: Current Biology - August 19, 2023 Category: Biology Authors: Olivier Duriez Yohan Sassi Chlo é Le Gall-Ladevèze L éa Giraud Robert Straughan Lise Dauvern é Anna Terras Thierry Boulinier R émi Choquet Anne Van De Wiele Julien Hirschinger Jean-Luc Gu érin Guillaume Le Loc'h Source Type: research
